Blood Pressure Reduction Per Milligram of Doxazosin
Doxazosin provides approximately 1.5-2 mmHg reduction in systolic blood pressure and 1-1.5 mmHg reduction in diastolic blood pressure per milligram when used as third-line or fourth-line antihypertensive therapy.
Evidence-Based BP Reduction Data
The most robust data comes from the ASCOT-BPLA trial, where doxazosin GITS was added as third-line therapy to patients already on a mean of 2.0 other antihypertensive drugs 1. At a mean final dose of 7.0 mg, doxazosin produced an 11.7/6.9 mmHg reduction from baseline BP of 158.7/89.2 mmHg. This translates to approximately 1.7 mmHg systolic and 1.0 mmHg diastolic reduction per milligram.
Additional supporting data:
- In Latin American general practice, doxazosin at a mean dose of 4.3 mg produced -18.4/-14.4 mmHg reduction, yielding approximately 4.3 mmHg systolic and 3.4 mmHg diastolic per milligram 2
- In French general practice, 3.4 mg mean dose achieved -15.4/-15.8 mmHg reduction, approximately 4.5 mmHg systolic and 4.6 mmHg diastolic per milligram 3
- When added to ACE inhibitor therapy, 2.4 mg mean dose produced 16/17 mmHg reduction, approximately 6.7 mmHg systolic and 7.1 mmHg diastolic per milligram 4
Clinical Context and Dosing
The FDA-approved dosing range is 1-16 mg once daily for hypertension 5. Maximum BP effects occur 2-6 hours post-dose, with trough effects at 24 hours representing approximately 55-70% of peak effect 5.
Important caveat: The per-milligram effect is not linear across the dose range. Higher baseline BP and fewer concurrent antihypertensive medications generally yield greater per-milligram reductions. The ASCOT data (third-line therapy) provides the most clinically relevant estimate for resistant hypertension scenarios.
Current Guideline Position
The 2025 AHA/ACC guidelines note that doxazosin is less effective than spironolactone as fourth-line therapy for resistant hypertension 6, 7. Spironolactone reduced 24-hour SBP by 6.6-8.7 mmHg compared to placebo, with greater BP reduction than doxazosin or bisoprolol in head-to-head trials. Doxazosin should be reserved for patients who cannot tolerate spironolactone, amiloride, or other preferred fourth-line agents.
Practical Application
For a patient requiring fourth-line therapy:
- Start at 1 mg daily and monitor BP for at least 6 hours post-dose 5
- Titrate at 1-2 week intervals to 2 mg, then 4 mg, then 8 mg as needed
- Expect approximately 10-12 mmHg systolic reduction at typical therapeutic doses (4-8 mg) when added to triple therapy
- Monitor for orthostatic hypotension, particularly in elderly patients, though normotensive BPH patients showed minimal BP lowering 5